Zu den Inhalten springen

Scientific Projects from the SMArtCARE Network

Scientific questions/research projects

The academic network around SMArtCARE aims to evaluate the long-term course of patients under therapy from a scientific point of view in order to gain additional knowledge about SMA, and the safety and the benefit of the drugs compared to other therapies.

Therefore, over the entire duration of the SMArtCARE data collection, the results obtained will be statistically evaluated and published in scientific journals. In these publications, no personally identifiable data (such as names or characteristics) will be published from which conclusions can be drawn about you or your child.

The following projects are currently underway:

1) Differences in disease age and severity between sibling pairs with comparable genetic backgrounds

    Dr. Benedikt Becker, Isabell Cordts, Prof. Dr. Marcus Deschauer

2) Evaluation of functional outcome in patients with 5q-associated spinal muscular atrophy after switching therapy from nusinersen to risdiplam compared to nusinersen continuous therapy

    Dr. Deike Weiss, Dr. Jessika, Johannsen, PD Dr. Jonas Denecke

3) Comparative analysis of data from patients on therapy with nusinersen or onasemnogen-abeparvovec and the influence of a change in therapy

    PD Dr. Astrid Pechmann, Prof. Dr. Janbernd Kirschner in cooperation with the Institute for Medical Biometry and Statistics (IMBI) of the University Medical Centre Freiburg

4) Multicentre long-term follow-up of patients > 12 years with 5q-SMA treated with risdiplam

    Prof. Dr. Maggie Walter

5) Parenthood, family planning, and pregnancy experience and outcomes in patients with Spinal Muscular Atrophy

    Prof. Dr. Maggie Walter, Simone Thiele

6) Current care landscape SMA without effectiveness data

    PD Dr. Astrid Pechmann, Prof. Dr. Jan Kirschner

7) Factors influencing airway involvement in spinal muscular atrophy type I to III  

    Dr. M. Groß, Prof. Summ, Dr. Grimm, Dr. Otto-Sobotka

8) Impact of SMN2-augmenting therapies on the hospitalization rate of adult patients with spinal muscular atrophy

    Dr. Benjamin Stolte, Prof. Dr. Tim Hagenacke